Signia Therapeutics is a spin-off of the VirPath Lab (University Claude Bernard Lyon 1, Lyon, France);  an academic research lab specialized on respiratory viruses.

---

Signia’s Founders

Manuel Rosa-Calatrava (Ph.D., INSERM researcher) is deputy director of the VirPath laboratory, director of the joint laboratory Biovirsafe and co-funder of the Virnext spin-off and the start-up VirHealth. He’s principal investigator of several research programs focusing on respiratory viruses and development of new antiviral strategies.

Olivier Terrier (Ph.D.) is a CNRS researcher in VirPath laboratory and co-funder of the start-up VirHealth. His work is focused on influenza and other respiratory viruses/host interactions to develop new antiviral strategies. He holds several patents in the field of microbiology & antivirals.

Guy Boivin (M.D. Ph.D.) is professor of microbiology-immunology at Laval University and a senior researcher in virology at the « Research Center in Infectious Diseases » of the same University. He holds the only Canadian Research Chair on emerging viruses and antiviral resistance. He is particularly interested in diagnosis, pathogenesis and treatment of viral infections.

Andrés Pizzorno (Ph.D.) is a postdoctoral researcher in the VirPath laboratory and co-inventor of several patents in the field of microbiology & antivirals. He works on the development, characterization and evaluation of in vitro/in vivo new therapeutic approaches directed against respiratory viruses.